Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases
- 13 October 2004
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 15 (6) , 557-563
- https://doi.org/10.1016/j.copbio.2004.09.005
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Successful tumor necrosis factor α blockade treatment in therapy‐resistant sarcoidosisArthritis & Rheumatism, 2003
- Efficacy of infliximab in resistant psoriatic arthritisArthritis Care & Research, 2003
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Anti-Cytokine Therapy for Rheumatoid ArthritisAnnual Review of Medicine, 2000
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000
- Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich ElementsImmunity, 1999
- Therapeutic actions of cyclosporine and anti-tumor necrosis factor ? in collagen-induced arthritis and the effect of combination therapyArthritis & Rheumatism, 1998
- Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea.Journal of Clinical Pathology, 1993